product recall

US Rival Makes Cochlear Shares Drop Anew


Cochlear (ASX:COH) shares crashed anew after rival Advanced Bionics (AB) made a comeback in the US market. Days after the biotech company recalled its Nucleus hearing implants, shares dropped over 15 percent to $51.01 before closing at $51.30, down 14.64 percent.

Cochlear Shares Dive After CI500 Recall


Hearing device company Cochlear (COH) saw its shares plummet yesterday after it declared a global recall of its Nucleus CI500 line due to a spike in product failure rates. Shares dropped over 20 percent to $57.50 as terrified investors sold out en masse.

The CI500 series accounts for about 70 percent of Cochlear sales and pulling it off the market cost the company more than $800 million in stock value.

Syndicate content

Recommended Websites